New tumour cases in Zolgensma recipients prompt fresh safety discussion at AHA
Novartis has disclosed additional tumour reports in children treated with its AAV-based SMA gene therapy, adding to a pharmacovigilance picture already noted by researchers and regulators.
Items [15] and [16] in this feed cover further tumour cases linked to Zolgensma (onasemnogene abeparvovec), Novartis's adeno-associated virus (AAV) gene therapy approved for spinal muscular atrophy (SMA). Item [15] from Stat News reports that new cases show AAV-based gene therapies carry tumour risks, with Novartis having disclosed additional previously unreported cases in children who received Zolgensma. Item [16] (the Stat News 'Readout' briefing) reiterates the Zolgensma tumour disclosure alongside an unrelated cardiovascular drug story.
This cluster builds on reporting already published by Genetic Current on 6 and 7 November 2026. The new Stat News item [15] adds detail on the broader implications for the AAV gene therapy field — not solely for SMA — and notes that researchers are now examining whether insertional mutagenesis or other mechanisms may underlie the association. No causal mechanism has been established. Zolgensma remains approved; regulatory agencies continue to monitor safety data. The findings are relevant to researchers in gene therapy and to genetic counsellors advising families who have received or are considering AAV-based treatments. Published guidance from regulators should be consulted for the most current safety information.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Zolgensma is a gene therapy used to treat spinal muscular atrophy (SMA), a rare inherited condition that affects muscle strength. It works by delivering a corrected copy of a gene using a carrier called an adeno-associated virus (AAV). Novartis, the company that makes Zolgensma, has reported additional cases of tumours (abnormal growths) in some children who received the therapy. Researchers are studying whether the gene therapy itself may be connected to these cases, though no definite cause has been confirmed. The therapy remains approved, and regulators are continuing to review safety information. This is an evolving area of research and pharmacovigilance — the ongoing monitoring of medicines after approval. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-11-06New tumor cases show common gene therapy tool can come with risk
-
Stat News · 2026-11-06Amgen's Repatha linked to fewer heart attacks